Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8375577 | 0.89 | DGAT1 (0.42) | ELANEDGAT1HDAC6USP2SMN1; SMN2 | |
| SCHEMBL5452 | 0.89 | DGAT1 (0.42) | ELANEDGAT1HDAC6USP2SMN1; SMN2 | |
| SCHEMBL1984289 | 0.87 | ELANE (0.35) | ELANEDGAT1HDAC6USP2SMN1; SMN2 | |
| SCHEMBL68474 | 0.86 | ELANE (0.38) | ELANEDGAT1HDAC6USP2SMN1; SMN2 | |
| Acetic Acid SCHEMBL28157839 | 0.86 | FFAR3 (0.39) | ELANEDGAT1HDAC6USP2SMN1; SMN2 | |
| SCHEMBL29482425 | 0.86 | DGAT1 (0.40) | ELANEDGAT1HDAC6USP2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28367906 | 0.86 | DGAT1 (0.40) | ELANEDGAT1HDAC6USP2SMN1; SMN2 | |
| SCHEMBL29808062 | 0.86 | DGAT1 (0.40) | ELANEDGAT1HDAC6USP2SMN1; SMN2 | |
| SCHEMBL31469549 | 0.86 | DGAT1 (0.40) | ELANEDGAT1HDAC6USP2SMN1; SMN2 | |
| SCHEMBL29740062 | 0.86 | DGAT1 (0.40) | ELANEDGAT1HDAC6USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112028825-B | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生睿创生物科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-3293177-B1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2024-11-27 | — | — | EP | disclosed |
| CN-112028825-A | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生睿创生物科技有限公司 | 2020-12-04 | — | — | CN | disclosed |
| CN-107683279-B | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生睿创生物科技有限公司 | 2020-11-03 | — | — | CN | disclosed |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
| CN-106046007-B | Tyrosine kinase inhibitor and pharmaceutical composition comprising the tyrosine kinase inhibitor | 广东众生睿创生物科技有限公司 | 2019-02-05 | — | — | CN | disclosed |
| EP-3293177-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
| CN-107683279-A | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生药业股份有限公司 | 2018-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ABL1, LCK, ERBB2 | ELANE 3708/4885DGAT1 3655/4885HDAC6 995/4885 |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | ABL1, LCK, ERBB2 | ELANE 3708/4885DGAT1 3655/4885HDAC6 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.